(TYRA) Tyra Biosciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.062m USD | Total Return: 238.6% in 12m
Avg Turnover: 27.5M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
Tyra Biosciences, Inc. is a California-based clinical-stage biotechnology firm specializing in precision medicines targeting fibroblast growth factor receptor (FGFR) biology. The company utilizes its proprietary SNÅP platform to design therapies by predicting genetic alterations through iterative molecular snapshots. Its primary focus involves developing treatments for oncology and rare skeletal conditions, such as achondroplasia and hypochondroplasia.
The companys pipeline is led by TYRA-300, a candidate currently in clinical trials for metastatic urothelial carcinoma and skeletal dysplasias. Other active programs include TYRA-200 for intrahepatic cholangiocarcinoma and TYRA-430 for hepatocellular carcinoma. Precision medicine in the biotechnology sector often aims to reduce off-target toxicities by engineering molecules that bind specifically to mutated proteins while sparing wild-type receptors.
The biotechnology industry operates on high R&D intensity, where success is heavily dependent on achieving specific clinical trial endpoints and securing regulatory approvals. Investors may find it useful to examine ValueRay for deeper insights into the companys valuation metrics and market position. Tyra Biosciences remains focused on addressing unmet medical needs through its structurally informed drug design approach.
- TYRA-300 clinical data readouts for achondroplasia and urothelial carcinoma drive valuation
- SNÅP platform efficiency determines speed of precision medicine pipeline development
- FDA regulatory milestones for FGFR3-targeted candidates impact long-term commercial viability
- R&D expenditure and cash burn rates influence future capital raise requirements
- Competitive pressure from established FGFR inhibitors affects potential market share capture
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA -3.40 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -102.3m > Net Income -131.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 20.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.7m) vs 12m ago 4.06% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.14%; Δ -0.14% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 394.6m - Total Current Liabilities 19.3m) / Total Assets 412.0m |
| B: -1.00 (Retained Earnings -410.6m / Total Assets 412.0m) |
| C: -0.37 (EBIT TTM -139.8m / Avg Total Assets 377.8m) |
| D: -16.78 (Book Value of Equity -410.4m / Total Liabilities 24.5m) |
| Altman-Z'' = -17.38 = D |
As of May 24, 2026, the stock is trading at USD 33.02 with a total of 609,654 shares traded.
Over the past week, the price has changed by -12.34%,
over one month by -13.07%,
over three months by -2.49% and
over the past year by +238.58%.
Tyra Biosciences has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy TYRA.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 51.2 | 54.9% |
Revenue TTM = 0.0 USD
EBIT TTM = -139.8m USD
EBITDA TTM = -139.3m USD
Long Term Debt = 5.21m USD (estimated: total debt 5.70m - short term 488k)
Short Term Debt = 488k USD (from shortTermDebt, last quarter)
Debt = 5.70m USD (from shortLongTermDebtTotal, last quarter) (leases 5.70m already included)
Net Debt = -377.8m USD (calculated: Debt 5.70m - CCE 383.5m)
Enterprise Value = 1.68b USD (2.06b + Debt 5.70m - CCE 383.5m)
Interest Coverage Ratio = unknown (Ebit TTM -139.8m / Interest Expense TTM 0.0)
EV/FCF = -16.44x (Enterprise Value 1.68b / FCF TTM -102.5m)
FCF Yield = -6.08% (FCF TTM -102.5m / Enterprise Value 1.68b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 546k) / Revenue TTM)
Tobins Q-Ratio = 4.09 (Enterprise Value 1.68b / Total Assets 412.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.70m)
Taxrate = 21.0% (US default 21%)
NOPAT = -110.5m (EBIT -139.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 20.49 (Total Current Assets 394.6m / Total Current Liabilities 19.3m)
Debt / Equity = 0.01 (Debt 5.70m / totalStockholderEquity, last quarter 387.6m)
Debt / EBITDA = 2.71 (negative EBITDA) (Net Debt -377.8m / EBITDA -139.3m)
Debt / FCF = 3.69 (negative FCF - burning cash) (Net Debt -377.8m / FCF TTM -102.5m)
Total Stockholder Equity = 307.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.71% (Net Income -131.1m / Total Assets 412.0m)
RoE = -18.26% (Net Income TTM -131.1m / Total Stockholder Equity 717.9m)
RoCE = -19.34% (EBIT -139.8m / Capital Employed (Equity 717.9m + L.T.Debt 5.21m))
RoIC = -40.28% (negative operating profit) (NOPAT -110.5m / Invested Capital 274.2m)
WACC = 10.56% (E(2.06b)/V(2.07b) * Re(10.59%) + D(5.70m)/V(2.07b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 17.49%
[DCF] Fair Price = unknown (Cash Flow -102.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.14 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.65 | Chg30d=-12.38% | Revisions=-54% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.66 | Chg30d=-10.61% | Revisions=-38% | Analysts=12
EPS current Year (2026-12-31): EPS=-2.61 | Chg30d=-12.66% | Revisions=-50% | GrowthEPS=-29.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.88 | Chg30d=-12.17% | Revisions=-54% | GrowthEPS=-10.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -54%